Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.12)
# 3,518
Out of 4,732 analysts
96
Total ratings
30.77%
Success rate
-15.26%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $10.86 | +38.12% | 3 | Jan 17, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $36 → $37 | $36.20 | +2.21% | 3 | Jan 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $54.80 | -3.28% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $3.45 | +189.86% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $40.29 | +73.74% | 2 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $95 → $105 | $91.84 | +14.33% | 4 | Nov 7, 2024 | |
| EPIX ESSA Pharma | Downgrades: Neutral | $15 → $2 | $1.75 | +14.29% | 2 | Nov 4, 2024 | |
| BMEA Biomea Fusion | Maintains: Overweight | $10 → $19 | $3.98 | +377.99% | 5 | Oct 31, 2024 | |
| IMTX Immatics | Initiates: Overweight | $19 | $5.35 | +255.14% | 1 | Oct 7, 2024 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $12 → $15 | $2.20 | +581.82% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $1.75 | $2.98 | -41.28% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.44 | +750.34% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $2.94 | +61.56% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $22.50 | +60.00% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $10 | $5.91 | +69.20% | 8 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $12.54 | +218.98% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.01 | +87.27% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $19.14 | +82.86% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $0.84 | +316.67% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.01 | +345.54% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $5.78 | +419.03% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.53 | +690.51% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.14 | +75.44% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $1.07 | +834.58% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $19.00 | +163.16% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.85 | +531.58% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.28 | +1,853.13% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $4.12 | -57.54% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $22.78 | -12.20% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.05 | +42.86% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.53 | +1,786.79% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.94 | +489.23% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $2.46 | +2,339.02% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $3.82 | +371.20% | 3 | Apr 7, 2020 |
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $10.86
Upside: +38.12%
Exelixis
Jan 13, 2025
Maintains: Overweight
Price Target: $36 → $37
Current: $36.20
Upside: +2.21%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $54.80
Upside: -3.28%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.45
Upside: +189.86%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $40.29
Upside: +73.74%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $95 → $105
Current: $91.84
Upside: +14.33%
ESSA Pharma
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.75
Upside: +14.29%
Biomea Fusion
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $3.98
Upside: +377.99%
Immatics
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.35
Upside: +255.14%
Black Diamond Therapeutics
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.20
Upside: +581.82%
Aug 27, 2024
Downgrades: Neutral
Price Target: $5 → $1.75
Current: $2.98
Upside: -41.28%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.44
Upside: +750.34%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $2.94
Upside: +61.56%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $22.50
Upside: +60.00%
Jul 29, 2024
Downgrades: Neutral
Price Target: $19 → $10
Current: $5.91
Upside: +69.20%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $12.54
Upside: +218.98%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.01
Upside: +87.27%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $19.14
Upside: +82.86%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $0.84
Upside: +316.67%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.01
Upside: +345.54%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $5.78
Upside: +419.03%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $2.53
Upside: +690.51%
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.14
Upside: +75.44%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $1.07
Upside: +834.58%
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $19.00
Upside: +163.16%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $2.85
Upside: +531.58%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.28
Upside: +1,853.13%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $4.12
Upside: -57.54%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $22.78
Upside: -12.20%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.05
Upside: +42.86%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.53
Upside: +1,786.79%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $5.94
Upside: +489.23%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $2.46
Upside: +2,339.02%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $3.82
Upside: +371.20%